Vertex Pharmaceuticals
VRTX
855 hedge funds and large institutions have $58.3B invested in Vertex Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 136 funds opening new positions, 331 increasing their positions, 273 reducing their positions, and 86 closing their positions.
78% more funds holding in top 10
Funds holding in top 10: 18 → 32 (+14)
58% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 86
21% more repeat investments, than reductions
Existing positions increased: 331 | Existing positions reduced: 273
16% more call options, than puts
Call options by funds: $306M | Put options by funds: $264M
5% more funds holding
Funds holding: 814 → 855 (+41)
8% more capital inflows, than outflows
Capital inflows: $3.29B | Capital outflows: $3.04B
0.4% less ownership
Funds ownership: 94.94% → 94.54% (-0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$455M |
| 2 |
BlackRock
New York
|
+$277M |
| 3 |
Jennison Associates
New York
|
+$181M |
| 4 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$145M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$118M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$666M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$276M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$134M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$122M |
| 5 |
Senator Investment Group
New York
|
-$98.5M |
VRTX Hedge Fund Activity: Q1 2020 in Review
855 of the 4,550 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2020, worth a combined $58.3B — up 9.1% from $53.4B a quarter earlier.
Buyers outnumbered sellers: 136 funds opened new VRTX positions and 86 closed out — a net gain of 50 holders — while 331 added to existing stakes and 273 trimmed.
The largest buyer was Capital World Investors, adding an estimated $455M. The largest seller was T. Rowe Price Associates, cutting an estimated $666M.
- 855 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2020, up from 814 in Q4 2019.
- Funds reported $58.3B of Vertex Pharmaceuticals stock for Q1 2020, up 9.1% quarter-over-quarter.
- 136 funds opened new Vertex Pharmaceuticals positions in Q1 2020 and 86 closed out, a net change of +50 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2020 was Capital World Investors, an estimated $455M added.
- The largest Vertex Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $666M sold.
Based on aggregated 13F filings for Q1 2020.